Ikarian Capital’s Dyne Therapeutics DYN Stock Holding History

Ikarian Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-187,000	Closed	-$1.96M	–	154
2025 Q1	$1.96M	Buy	+187,000	New	+$2.67M	0.24%	68
2024 Q1	–	Sell	-607,600	Closed	-$8.08M	–	153
2023 Q4	$8.08M	Buy	607,600 +604,874	+22,189%	+$5.91M	0.76%	46
2023 Q3	$2.44M	Buy	+2,726	New	+$29.4K	0.29%	75

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Ikarian Capital's DYN Position: Q4 2025 in Review

Ikarian Capital sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 113,837 shares — an estimated $1.44M sold.

Ikarian Capital first reported a position in DYN in Q4 2023 and held it in 4 quarters. The position peaked at $3.8M in Q4 2023. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

Ikarian Capital reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 113,837 Dyne Therapeutics shares in Q4 2025, an estimated $1.44M.
Ikarian Capital first reported a position in Dyne Therapeutics in Q4 2023 and held it in 4 quarters.
Ikarian Capital's Dyne Therapeutics position peaked at $3.8M in Q4 2023.
232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.